Drug Trial Radar · NCT06926673
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Dec 23, 2021
Primary completion
May 2, 2024
Study completion May 2, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.
Conditions
- Neoplasms
Interventions
DostarlimabDrug
Dostarlimab will be administered
Belrestotug.Drug
Belrestotug will be administered
NelistotugDrug
Nelistotug will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Any TEAEs and SAEs (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5)Time frame: Up to 21 days
- Part 1: Number of Participants Requiring Dose Modifications (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants Requiring Dose Modifications (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants Who Received Concomitant Medications (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants Who Received Concomitant Medications (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline Electrocardiogram (ECG) Findings (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline ECG Findings (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 5)Time frame: Up to approximately 107 weeks
- Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 4)Time frame: Up to approximately 97 weeks
- Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 5)Time frame: Up to approximately 107 weeks
- Part 2: Overall Survival (OS)Time frame: Up to approximately 107 weeks
Locations
15 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational SIte
Nashville, Tennessee
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Großhansdorf, Germany
GSK Investigational Site
Meldola FC, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Siena, Italy
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Málaga, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.